SCHEMBL7149643

SCHEMBL7149643

COc1ccc2nc(SCS(=O)(=O)Nc3ccccc3C)sc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.50
LMNA P02545 6/20 0.47
ALDH1A1 P00352 4/20 0.47
PKM P14618 1/20 0.47
MAPT P10636 12/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
MAPK1 P28482 1/20 0.45
KMT2A Q03164 8/20 0.45
MEN1 O00255 7/20 0.45
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
NFKB1 P19838 2/20 0.45
NFKB2 Q00653 2/20 0.45
RELA Q04206 2/20 0.45
GFER P55789 1/20 0.45
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
CTSK P43235 1/20 0.44
KEAP1 Q14145 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7154156 0.90 MAPT (0.48) PDK1LMNAALDH1A1PKMMAPT
SCHEMBL7153200 0.90 MAPT (0.55) PDK1LMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL7152196 0.88 MAPT (0.49) PDK1LMNAALDH1A1PKMMAPT
SCHEMBL7151731 0.88 MAPT (0.48) PDK1LMNAALDH1A1PKMMAPT
SCHEMBL7147603 0.85 LMNA (0.57) LMNAALDH1A1MAPTSMN1; SMN2L3MBTL1
SCHEMBL7151274 0.84 PDK1 (0.55) PDK1LMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL7149250 0.83 PDK1 (0.52) PDK1LMNAMAPTSMN1; SMN2L3MBTL1
SCHEMBL7149256 0.83 MAPT (0.54) PDK1LMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL7149774 0.83 MAPT (0.50) PDK1LMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL7144783 0.81 LMNA (0.46) LMNAALDH1A1PKMMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 PDK1 4188/4885LMNA 1481/4885ALDH1A1 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.